Global Immuno-oncology Drugs Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
LPI (LP Information)' newest research report, the “Immuno-oncology Drugs Industry Forecast” looks at past sales and reviews total world Immuno-oncology Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Immuno-oncology Drugs sales for 2023 through 2029. With Immuno-oncology Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immuno-oncology Drugs industry.
This Insight Report provides a comprehensive analysis of the global Immuno-oncology Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immuno-oncology Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Immuno-oncology Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immuno-oncology Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immuno-oncology Drugs.
The global Immuno-oncology Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Immuno-oncology Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Immuno-oncology Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Immuno-oncology Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Immuno-oncology Drugs players cover Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Immuno-oncology Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Immuno-oncology Drugs market?
What factors are driving Immuno-oncology Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immuno-oncology Drugs market opportunities vary by end market size?
How does Immuno-oncology Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
LPI (LP Information)' newest research report, the “Immuno-oncology Drugs Industry Forecast” looks at past sales and reviews total world Immuno-oncology Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Immuno-oncology Drugs sales for 2023 through 2029. With Immuno-oncology Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immuno-oncology Drugs industry.
This Insight Report provides a comprehensive analysis of the global Immuno-oncology Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immuno-oncology Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Immuno-oncology Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immuno-oncology Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immuno-oncology Drugs.
The global Immuno-oncology Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Immuno-oncology Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Immuno-oncology Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Immuno-oncology Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Immuno-oncology Drugs players cover Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Immuno-oncology Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Oncolytic Virus
- Others
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen, Inc
- AstraZeneca, Plc
- Bristol-Myers Squibb
- Celgene Corporation
- Eli Lilly and Company
- Merck & Co.
- Hoffmann-La Roche AG
- Johnson & Johnson
- Novartis International AG
- AbbVie, Inc.
- Pfizer Inc.
- Sanofi S.A.
- EMD Serono, Inc.
- Gilead Sciences Inc.
- Prometheus Therapeutics & Diagnostics
- Aduro BioTech
- Galena Biopharma
- Bavarian Nordic
- Celldex Therapeutics
- ImmunoCellular Therapeutics
- Incyte
- Dendreon Corporation
- Agilent Technologies Inc.
- Agenus Inc.
- Enzo Biochem, Inc.
- Lonza Group
- Bio-Rad Laboratories, Inc.
- Avantor, Inc.
- Spring Bank Pharmaceuticals, Inc.
- Ferring Pharmaceuticals
What is the 10-year outlook for the global Immuno-oncology Drugs market?
What factors are driving Immuno-oncology Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Immuno-oncology Drugs market opportunities vary by end market size?
How does Immuno-oncology Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immuno-oncology Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Immuno-oncology Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Immuno-oncology Drugs by Country/Region, 2018, 2022 & 2029
2.2 Immuno-oncology Drugs Segment by Type
2.2.1 Immune Checkpoint Inhibitors
2.2.2 Immune System Modulators
2.2.3 Cancer Vaccines
2.2.4 Oncolytic Virus
2.2.5 Others
2.3 Immuno-oncology Drugs Sales by Type
2.3.1 Global Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Immuno-oncology Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Immuno-oncology Drugs Sale Price by Type (2018-2023)
2.4 Immuno-oncology Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Ambulatory Surgical Centers
2.5 Immuno-oncology Drugs Sales by Application
2.5.1 Global Immuno-oncology Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Immuno-oncology Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Immuno-oncology Drugs Sale Price by Application (2018-2023)
3 GLOBAL IMMUNO-ONCOLOGY DRUGS BY COMPANY
3.1 Global Immuno-oncology Drugs Breakdown Data by Company
3.1.1 Global Immuno-oncology Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Immuno-oncology Drugs Sales Market Share by Company (2018-2023)
3.2 Global Immuno-oncology Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Immuno-oncology Drugs Revenue by Company (2018-2023)
3.2.2 Global Immuno-oncology Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Immuno-oncology Drugs Sale Price by Company
3.4 Key Manufacturers Immuno-oncology Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immuno-oncology Drugs Product Location Distribution
3.4.2 Players Immuno-oncology Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR IMMUNO-ONCOLOGY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Immuno-oncology Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Immuno-oncology Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Immuno-oncology Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Immuno-oncology Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Immuno-oncology Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Immuno-oncology Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Immuno-oncology Drugs Sales Growth
4.4 APAC Immuno-oncology Drugs Sales Growth
4.5 Europe Immuno-oncology Drugs Sales Growth
4.6 Middle East & Africa Immuno-oncology Drugs Sales Growth
5 AMERICAS
5.1 Americas Immuno-oncology Drugs Sales by Country
5.1.1 Americas Immuno-oncology Drugs Sales by Country (2018-2023)
5.1.2 Americas Immuno-oncology Drugs Revenue by Country (2018-2023)
5.2 Americas Immuno-oncology Drugs Sales by Type
5.3 Americas Immuno-oncology Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immuno-oncology Drugs Sales by Region
6.1.1 APAC Immuno-oncology Drugs Sales by Region (2018-2023)
6.1.2 APAC Immuno-oncology Drugs Revenue by Region (2018-2023)
6.2 APAC Immuno-oncology Drugs Sales by Type
6.3 APAC Immuno-oncology Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Immuno-oncology Drugs by Country
7.1.1 Europe Immuno-oncology Drugs Sales by Country (2018-2023)
7.1.2 Europe Immuno-oncology Drugs Revenue by Country (2018-2023)
7.2 Europe Immuno-oncology Drugs Sales by Type
7.3 Europe Immuno-oncology Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immuno-oncology Drugs by Country
8.1.1 Middle East & Africa Immuno-oncology Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Immuno-oncology Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Immuno-oncology Drugs Sales by Type
8.3 Middle East & Africa Immuno-oncology Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immuno-oncology Drugs
10.3 Manufacturing Process Analysis of Immuno-oncology Drugs
10.4 Industry Chain Structure of Immuno-oncology Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immuno-oncology Drugs Distributors
11.3 Immuno-oncology Drugs Customer
12 WORLD FORECAST REVIEW FOR IMMUNO-ONCOLOGY DRUGS BY GEOGRAPHIC REGION
12.1 Global Immuno-oncology Drugs Market Size Forecast by Region
12.1.1 Global Immuno-oncology Drugs Forecast by Region (2024-2029)
12.1.2 Global Immuno-oncology Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Immuno-oncology Drugs Forecast by Type
12.7 Global Immuno-oncology Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen, Inc
13.1.1 Amgen, Inc Company Information
13.1.2 Amgen, Inc Immuno-oncology Drugs Product Portfolios and Specifications
13.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amgen, Inc Main Business Overview
13.1.5 Amgen, Inc Latest Developments
13.2 AstraZeneca, Plc
13.2.1 AstraZeneca, Plc Company Information
13.2.2 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca, Plc Main Business Overview
13.2.5 AstraZeneca, Plc Latest Developments
13.3 Bristol-Myers Squibb
13.3.1 Bristol-Myers Squibb Company Information
13.3.2 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Bristol-Myers Squibb Main Business Overview
13.3.5 Bristol-Myers Squibb Latest Developments
13.4 Celgene Corporation
13.4.1 Celgene Corporation Company Information
13.4.2 Celgene Corporation Immuno-oncology Drugs Product Portfolios and Specifications
13.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Celgene Corporation Main Business Overview
13.4.5 Celgene Corporation Latest Developments
13.5 Eli Lilly and Company
13.5.1 Eli Lilly and Company Company Information
13.5.2 Eli Lilly and Company Immuno-oncology Drugs Product Portfolios and Specifications
13.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly and Company Main Business Overview
13.5.5 Eli Lilly and Company Latest Developments
13.6 Merck & Co.
13.6.1 Merck & Co. Company Information
13.6.2 Merck & Co. Immuno-oncology Drugs Product Portfolios and Specifications
13.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Merck & Co. Main Business Overview
13.6.5 Merck & Co. Latest Developments
13.7 Hoffmann-La Roche AG
13.7.1 Hoffmann-La Roche AG Company Information
13.7.2 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolios and Specifications
13.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Hoffmann-La Roche AG Main Business Overview
13.7.5 Hoffmann-La Roche AG Latest Developments
13.8 Johnson & Johnson
13.8.1 Johnson & Johnson Company Information
13.8.2 Johnson & Johnson Immuno-oncology Drugs Product Portfolios and Specifications
13.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Johnson & Johnson Main Business Overview
13.8.5 Johnson & Johnson Latest Developments
13.9 Novartis International AG
13.9.1 Novartis International AG Company Information
13.9.2 Novartis International AG Immuno-oncology Drugs Product Portfolios and Specifications
13.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novartis International AG Main Business Overview
13.9.5 Novartis International AG Latest Developments
13.10 AbbVie, Inc.
13.10.1 AbbVie, Inc. Company Information
13.10.2 AbbVie, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 AbbVie, Inc. Main Business Overview
13.10.5 AbbVie, Inc. Latest Developments
13.11 Pfizer Inc.
13.11.1 Pfizer Inc. Company Information
13.11.2 Pfizer Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Pfizer Inc. Main Business Overview
13.11.5 Pfizer Inc. Latest Developments
13.12 Sanofi S.A.
13.12.1 Sanofi S.A. Company Information
13.12.2 Sanofi S.A. Immuno-oncology Drugs Product Portfolios and Specifications
13.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sanofi S.A. Main Business Overview
13.12.5 Sanofi S.A. Latest Developments
13.13 EMD Serono, Inc.
13.13.1 EMD Serono, Inc. Company Information
13.13.2 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 EMD Serono, Inc. Main Business Overview
13.13.5 EMD Serono, Inc. Latest Developments
13.14 Gilead Sciences Inc.
13.14.1 Gilead Sciences Inc. Company Information
13.14.2 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Gilead Sciences Inc. Main Business Overview
13.14.5 Gilead Sciences Inc. Latest Developments
13.15 Prometheus Therapeutics & Diagnostics
13.15.1 Prometheus Therapeutics & Diagnostics Company Information
13.15.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolios and Specifications
13.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Prometheus Therapeutics & Diagnostics Main Business Overview
13.15.5 Prometheus Therapeutics & Diagnostics Latest Developments
13.16 Aduro BioTech
13.16.1 Aduro BioTech Company Information
13.16.2 Aduro BioTech Immuno-oncology Drugs Product Portfolios and Specifications
13.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Aduro BioTech Main Business Overview
13.16.5 Aduro BioTech Latest Developments
13.17 Galena Biopharma
13.17.1 Galena Biopharma Company Information
13.17.2 Galena Biopharma Immuno-oncology Drugs Product Portfolios and Specifications
13.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Galena Biopharma Main Business Overview
13.17.5 Galena Biopharma Latest Developments
13.18 Bavarian Nordic
13.18.1 Bavarian Nordic Company Information
13.18.2 Bavarian Nordic Immuno-oncology Drugs Product Portfolios and Specifications
13.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Bavarian Nordic Main Business Overview
13.18.5 Bavarian Nordic Latest Developments
13.19 Celldex Therapeutics
13.19.1 Celldex Therapeutics Company Information
13.19.2 Celldex Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
13.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Celldex Therapeutics Main Business Overview
13.19.5 Celldex Therapeutics Latest Developments
13.20 ImmunoCellular Therapeutics
13.20.1 ImmunoCellular Therapeutics Company Information
13.20.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
13.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 ImmunoCellular Therapeutics Main Business Overview
13.20.5 ImmunoCellular Therapeutics Latest Developments
13.21 Incyte
13.21.1 Incyte Company Information
13.21.2 Incyte Immuno-oncology Drugs Product Portfolios and Specifications
13.21.3 Incyte Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Incyte Main Business Overview
13.21.5 Incyte Latest Developments
13.22 Dendreon Corporation
13.22.1 Dendreon Corporation Company Information
13.22.2 Dendreon Corporation Immuno-oncology Drugs Product Portfolios and Specifications
13.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Dendreon Corporation Main Business Overview
13.22.5 Dendreon Corporation Latest Developments
13.23 Agilent Technologies Inc.
13.23.1 Agilent Technologies Inc. Company Information
13.23.2 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Agilent Technologies Inc. Main Business Overview
13.23.5 Agilent Technologies Inc. Latest Developments
13.24 Agenus Inc.
13.24.1 Agenus Inc. Company Information
13.24.2 Agenus Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 Agenus Inc. Main Business Overview
13.24.5 Agenus Inc. Latest Developments
13.25 Enzo Biochem, Inc.
13.25.1 Enzo Biochem, Inc. Company Information
13.25.2 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 Enzo Biochem, Inc. Main Business Overview
13.25.5 Enzo Biochem, Inc. Latest Developments
13.26 Lonza Group
13.26.1 Lonza Group Company Information
13.26.2 Lonza Group Immuno-oncology Drugs Product Portfolios and Specifications
13.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 Lonza Group Main Business Overview
13.26.5 Lonza Group Latest Developments
13.27 Bio-Rad Laboratories, Inc.
13.27.1 Bio-Rad Laboratories, Inc. Company Information
13.27.2 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.27.4 Bio-Rad Laboratories, Inc. Main Business Overview
13.27.5 Bio-Rad Laboratories, Inc. Latest Developments
13.28 Avantor, Inc.
13.28.1 Avantor, Inc. Company Information
13.28.2 Avantor, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.28.4 Avantor, Inc. Main Business Overview
13.28.5 Avantor, Inc. Latest Developments
13.29 Spring Bank Pharmaceuticals, Inc.
13.29.1 Spring Bank Pharmaceuticals, Inc. Company Information
13.29.2 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.29.4 Spring Bank Pharmaceuticals, Inc. Main Business Overview
13.29.5 Spring Bank Pharmaceuticals, Inc. Latest Developments
13.30 Ferring Pharmaceuticals
13.30.1 Ferring Pharmaceuticals Company Information
13.30.2 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolios and Specifications
13.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.30.4 Ferring Pharmaceuticals Main Business Overview
13.30.5 Ferring Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immuno-oncology Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Immuno-oncology Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Immuno-oncology Drugs by Country/Region, 2018, 2022 & 2029
2.2 Immuno-oncology Drugs Segment by Type
2.2.1 Immune Checkpoint Inhibitors
2.2.2 Immune System Modulators
2.2.3 Cancer Vaccines
2.2.4 Oncolytic Virus
2.2.5 Others
2.3 Immuno-oncology Drugs Sales by Type
2.3.1 Global Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Immuno-oncology Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Immuno-oncology Drugs Sale Price by Type (2018-2023)
2.4 Immuno-oncology Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Ambulatory Surgical Centers
2.5 Immuno-oncology Drugs Sales by Application
2.5.1 Global Immuno-oncology Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Immuno-oncology Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Immuno-oncology Drugs Sale Price by Application (2018-2023)
3 GLOBAL IMMUNO-ONCOLOGY DRUGS BY COMPANY
3.1 Global Immuno-oncology Drugs Breakdown Data by Company
3.1.1 Global Immuno-oncology Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Immuno-oncology Drugs Sales Market Share by Company (2018-2023)
3.2 Global Immuno-oncology Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Immuno-oncology Drugs Revenue by Company (2018-2023)
3.2.2 Global Immuno-oncology Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Immuno-oncology Drugs Sale Price by Company
3.4 Key Manufacturers Immuno-oncology Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immuno-oncology Drugs Product Location Distribution
3.4.2 Players Immuno-oncology Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR IMMUNO-ONCOLOGY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Immuno-oncology Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Immuno-oncology Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Immuno-oncology Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Immuno-oncology Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Immuno-oncology Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Immuno-oncology Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Immuno-oncology Drugs Sales Growth
4.4 APAC Immuno-oncology Drugs Sales Growth
4.5 Europe Immuno-oncology Drugs Sales Growth
4.6 Middle East & Africa Immuno-oncology Drugs Sales Growth
5 AMERICAS
5.1 Americas Immuno-oncology Drugs Sales by Country
5.1.1 Americas Immuno-oncology Drugs Sales by Country (2018-2023)
5.1.2 Americas Immuno-oncology Drugs Revenue by Country (2018-2023)
5.2 Americas Immuno-oncology Drugs Sales by Type
5.3 Americas Immuno-oncology Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immuno-oncology Drugs Sales by Region
6.1.1 APAC Immuno-oncology Drugs Sales by Region (2018-2023)
6.1.2 APAC Immuno-oncology Drugs Revenue by Region (2018-2023)
6.2 APAC Immuno-oncology Drugs Sales by Type
6.3 APAC Immuno-oncology Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Immuno-oncology Drugs by Country
7.1.1 Europe Immuno-oncology Drugs Sales by Country (2018-2023)
7.1.2 Europe Immuno-oncology Drugs Revenue by Country (2018-2023)
7.2 Europe Immuno-oncology Drugs Sales by Type
7.3 Europe Immuno-oncology Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immuno-oncology Drugs by Country
8.1.1 Middle East & Africa Immuno-oncology Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Immuno-oncology Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Immuno-oncology Drugs Sales by Type
8.3 Middle East & Africa Immuno-oncology Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immuno-oncology Drugs
10.3 Manufacturing Process Analysis of Immuno-oncology Drugs
10.4 Industry Chain Structure of Immuno-oncology Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immuno-oncology Drugs Distributors
11.3 Immuno-oncology Drugs Customer
12 WORLD FORECAST REVIEW FOR IMMUNO-ONCOLOGY DRUGS BY GEOGRAPHIC REGION
12.1 Global Immuno-oncology Drugs Market Size Forecast by Region
12.1.1 Global Immuno-oncology Drugs Forecast by Region (2024-2029)
12.1.2 Global Immuno-oncology Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Immuno-oncology Drugs Forecast by Type
12.7 Global Immuno-oncology Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen, Inc
13.1.1 Amgen, Inc Company Information
13.1.2 Amgen, Inc Immuno-oncology Drugs Product Portfolios and Specifications
13.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Amgen, Inc Main Business Overview
13.1.5 Amgen, Inc Latest Developments
13.2 AstraZeneca, Plc
13.2.1 AstraZeneca, Plc Company Information
13.2.2 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolios and Specifications
13.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 AstraZeneca, Plc Main Business Overview
13.2.5 AstraZeneca, Plc Latest Developments
13.3 Bristol-Myers Squibb
13.3.1 Bristol-Myers Squibb Company Information
13.3.2 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolios and Specifications
13.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Bristol-Myers Squibb Main Business Overview
13.3.5 Bristol-Myers Squibb Latest Developments
13.4 Celgene Corporation
13.4.1 Celgene Corporation Company Information
13.4.2 Celgene Corporation Immuno-oncology Drugs Product Portfolios and Specifications
13.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Celgene Corporation Main Business Overview
13.4.5 Celgene Corporation Latest Developments
13.5 Eli Lilly and Company
13.5.1 Eli Lilly and Company Company Information
13.5.2 Eli Lilly and Company Immuno-oncology Drugs Product Portfolios and Specifications
13.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly and Company Main Business Overview
13.5.5 Eli Lilly and Company Latest Developments
13.6 Merck & Co.
13.6.1 Merck & Co. Company Information
13.6.2 Merck & Co. Immuno-oncology Drugs Product Portfolios and Specifications
13.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Merck & Co. Main Business Overview
13.6.5 Merck & Co. Latest Developments
13.7 Hoffmann-La Roche AG
13.7.1 Hoffmann-La Roche AG Company Information
13.7.2 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolios and Specifications
13.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Hoffmann-La Roche AG Main Business Overview
13.7.5 Hoffmann-La Roche AG Latest Developments
13.8 Johnson & Johnson
13.8.1 Johnson & Johnson Company Information
13.8.2 Johnson & Johnson Immuno-oncology Drugs Product Portfolios and Specifications
13.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Johnson & Johnson Main Business Overview
13.8.5 Johnson & Johnson Latest Developments
13.9 Novartis International AG
13.9.1 Novartis International AG Company Information
13.9.2 Novartis International AG Immuno-oncology Drugs Product Portfolios and Specifications
13.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Novartis International AG Main Business Overview
13.9.5 Novartis International AG Latest Developments
13.10 AbbVie, Inc.
13.10.1 AbbVie, Inc. Company Information
13.10.2 AbbVie, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 AbbVie, Inc. Main Business Overview
13.10.5 AbbVie, Inc. Latest Developments
13.11 Pfizer Inc.
13.11.1 Pfizer Inc. Company Information
13.11.2 Pfizer Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Pfizer Inc. Main Business Overview
13.11.5 Pfizer Inc. Latest Developments
13.12 Sanofi S.A.
13.12.1 Sanofi S.A. Company Information
13.12.2 Sanofi S.A. Immuno-oncology Drugs Product Portfolios and Specifications
13.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Sanofi S.A. Main Business Overview
13.12.5 Sanofi S.A. Latest Developments
13.13 EMD Serono, Inc.
13.13.1 EMD Serono, Inc. Company Information
13.13.2 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 EMD Serono, Inc. Main Business Overview
13.13.5 EMD Serono, Inc. Latest Developments
13.14 Gilead Sciences Inc.
13.14.1 Gilead Sciences Inc. Company Information
13.14.2 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Gilead Sciences Inc. Main Business Overview
13.14.5 Gilead Sciences Inc. Latest Developments
13.15 Prometheus Therapeutics & Diagnostics
13.15.1 Prometheus Therapeutics & Diagnostics Company Information
13.15.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolios and Specifications
13.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Prometheus Therapeutics & Diagnostics Main Business Overview
13.15.5 Prometheus Therapeutics & Diagnostics Latest Developments
13.16 Aduro BioTech
13.16.1 Aduro BioTech Company Information
13.16.2 Aduro BioTech Immuno-oncology Drugs Product Portfolios and Specifications
13.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Aduro BioTech Main Business Overview
13.16.5 Aduro BioTech Latest Developments
13.17 Galena Biopharma
13.17.1 Galena Biopharma Company Information
13.17.2 Galena Biopharma Immuno-oncology Drugs Product Portfolios and Specifications
13.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Galena Biopharma Main Business Overview
13.17.5 Galena Biopharma Latest Developments
13.18 Bavarian Nordic
13.18.1 Bavarian Nordic Company Information
13.18.2 Bavarian Nordic Immuno-oncology Drugs Product Portfolios and Specifications
13.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Bavarian Nordic Main Business Overview
13.18.5 Bavarian Nordic Latest Developments
13.19 Celldex Therapeutics
13.19.1 Celldex Therapeutics Company Information
13.19.2 Celldex Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
13.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Celldex Therapeutics Main Business Overview
13.19.5 Celldex Therapeutics Latest Developments
13.20 ImmunoCellular Therapeutics
13.20.1 ImmunoCellular Therapeutics Company Information
13.20.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
13.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 ImmunoCellular Therapeutics Main Business Overview
13.20.5 ImmunoCellular Therapeutics Latest Developments
13.21 Incyte
13.21.1 Incyte Company Information
13.21.2 Incyte Immuno-oncology Drugs Product Portfolios and Specifications
13.21.3 Incyte Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Incyte Main Business Overview
13.21.5 Incyte Latest Developments
13.22 Dendreon Corporation
13.22.1 Dendreon Corporation Company Information
13.22.2 Dendreon Corporation Immuno-oncology Drugs Product Portfolios and Specifications
13.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Dendreon Corporation Main Business Overview
13.22.5 Dendreon Corporation Latest Developments
13.23 Agilent Technologies Inc.
13.23.1 Agilent Technologies Inc. Company Information
13.23.2 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Agilent Technologies Inc. Main Business Overview
13.23.5 Agilent Technologies Inc. Latest Developments
13.24 Agenus Inc.
13.24.1 Agenus Inc. Company Information
13.24.2 Agenus Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 Agenus Inc. Main Business Overview
13.24.5 Agenus Inc. Latest Developments
13.25 Enzo Biochem, Inc.
13.25.1 Enzo Biochem, Inc. Company Information
13.25.2 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 Enzo Biochem, Inc. Main Business Overview
13.25.5 Enzo Biochem, Inc. Latest Developments
13.26 Lonza Group
13.26.1 Lonza Group Company Information
13.26.2 Lonza Group Immuno-oncology Drugs Product Portfolios and Specifications
13.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 Lonza Group Main Business Overview
13.26.5 Lonza Group Latest Developments
13.27 Bio-Rad Laboratories, Inc.
13.27.1 Bio-Rad Laboratories, Inc. Company Information
13.27.2 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.27.4 Bio-Rad Laboratories, Inc. Main Business Overview
13.27.5 Bio-Rad Laboratories, Inc. Latest Developments
13.28 Avantor, Inc.
13.28.1 Avantor, Inc. Company Information
13.28.2 Avantor, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.28.4 Avantor, Inc. Main Business Overview
13.28.5 Avantor, Inc. Latest Developments
13.29 Spring Bank Pharmaceuticals, Inc.
13.29.1 Spring Bank Pharmaceuticals, Inc. Company Information
13.29.2 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
13.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.29.4 Spring Bank Pharmaceuticals, Inc. Main Business Overview
13.29.5 Spring Bank Pharmaceuticals, Inc. Latest Developments
13.30 Ferring Pharmaceuticals
13.30.1 Ferring Pharmaceuticals Company Information
13.30.2 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolios and Specifications
13.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.30.4 Ferring Pharmaceuticals Main Business Overview
13.30.5 Ferring Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Immuno-oncology Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Immuno-oncology Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Immune Checkpoint Inhibitors
Table 4. Major Players of Immune System Modulators
Table 5. Major Players of Cancer Vaccines
Table 6. Major Players of Oncolytic Virus
Table 7. Major Players of Others
Table 8. Global Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 9. Global Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Table 10. Global Immuno-oncology Drugs Revenue by Type (2018-2023) & ($ million)
Table 11. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2023)
Table 12. Global Immuno-oncology Drugs Sale Price by Type (2018-2023) & (USD/Unit)
Table 13. Global Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 14. Global Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Table 15. Global Immuno-oncology Drugs Revenue by Application (2018-2023)
Table 16. Global Immuno-oncology Drugs Revenue Market Share by Application (2018-2023)
Table 17. Global Immuno-oncology Drugs Sale Price by Application (2018-2023) & (USD/Unit)
Table 18. Global Immuno-oncology Drugs Sales by Company (2018-2023) & (K Units)
Table 19. Global Immuno-oncology Drugs Sales Market Share by Company (2018-2023)
Table 20. Global Immuno-oncology Drugs Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Immuno-oncology Drugs Revenue Market Share by Company (2018-2023)
Table 22. Global Immuno-oncology Drugs Sale Price by Company (2018-2023) & (USD/Unit)
Table 23. Key Manufacturers Immuno-oncology Drugs Producing Area Distribution and Sales Area
Table 24. Players Immuno-oncology Drugs Products Offered
Table 25. Immuno-oncology Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Immuno-oncology Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Immuno-oncology Drugs Sales Market Share Geographic Region (2018-2023)
Table 30. Global Immuno-oncology Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Immuno-oncology Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Immuno-oncology Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Immuno-oncology Drugs Sales Market Share by Country/Region (2018-2023)
Table 34. Global Immuno-oncology Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Immuno-oncology Drugs Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Immuno-oncology Drugs Sales by Country (2018-2023) & (K Units)
Table 37. Americas Immuno-oncology Drugs Sales Market Share by Country (2018-2023)
Table 38. Americas Immuno-oncology Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Immuno-oncology Drugs Revenue Market Share by Country (2018-2023)
Table 40. Americas Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 41. Americas Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 42. APAC Immuno-oncology Drugs Sales by Region (2018-2023) & (K Units)
Table 43. APAC Immuno-oncology Drugs Sales Market Share by Region (2018-2023)
Table 44. APAC Immuno-oncology Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Immuno-oncology Drugs Revenue Market Share by Region (2018-2023)
Table 46. APAC Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 47. APAC Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 48. Europe Immuno-oncology Drugs Sales by Country (2018-2023) & (K Units)
Table 49. Europe Immuno-oncology Drugs Sales Market Share by Country (2018-2023)
Table 50. Europe Immuno-oncology Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Immuno-oncology Drugs Revenue Market Share by Country (2018-2023)
Table 52. Europe Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 53. Europe Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Immuno-oncology Drugs Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Immuno-oncology Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Immuno-oncology Drugs Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Immuno-oncology Drugs
Table 61. Key Market Challenges & Risks of Immuno-oncology Drugs
Table 62. Key Industry Trends of Immuno-oncology Drugs
Table 63. Immuno-oncology Drugs Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Immuno-oncology Drugs Distributors List
Table 66. Immuno-oncology Drugs Customer List
Table 67. Global Immuno-oncology Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Immuno-oncology Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Immuno-oncology Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Immuno-oncology Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Immuno-oncology Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Immuno-oncology Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Immuno-oncology Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Immuno-oncology Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Immuno-oncology Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Immuno-oncology Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Immuno-oncology Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Immuno-oncology Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Immuno-oncology Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Immuno-oncology Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Amgen, Inc Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Amgen, Inc Immuno-oncology Drugs Product Portfolios and Specifications
Table 83. Amgen, Inc Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. Amgen, Inc Main Business
Table 85. Amgen, Inc Latest Developments
Table 86. AstraZeneca, Plc Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolios and Specifications
Table 88. AstraZeneca, Plc Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. AstraZeneca, Plc Main Business
Table 90. AstraZeneca, Plc Latest Developments
Table 91. Bristol-Myers Squibb Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolios and Specifications
Table 93. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. Bristol-Myers Squibb Main Business
Table 95. Bristol-Myers Squibb Latest Developments
Table 96. Celgene Corporation Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Celgene Corporation Immuno-oncology Drugs Product Portfolios and Specifications
Table 98. Celgene Corporation Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. Celgene Corporation Main Business
Table 100. Celgene Corporation Latest Developments
Table 101. Eli Lilly and Company Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Eli Lilly and Company Immuno-oncology Drugs Product Portfolios and Specifications
Table 103. Eli Lilly and Company Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. Eli Lilly and Company Main Business
Table 105. Eli Lilly and Company Latest Developments
Table 106. Merck & Co. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Merck & Co. Immuno-oncology Drugs Product Portfolios and Specifications
Table 108. Merck & Co. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. Merck & Co. Main Business
Table 110. Merck & Co. Latest Developments
Table 111. Hoffmann-La Roche AG Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolios and Specifications
Table 113. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 114. Hoffmann-La Roche AG Main Business
Table 115. Hoffmann-La Roche AG Latest Developments
Table 116. Johnson & Johnson Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Johnson & Johnson Immuno-oncology Drugs Product Portfolios and Specifications
Table 118. Johnson & Johnson Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 119. Johnson & Johnson Main Business
Table 120. Johnson & Johnson Latest Developments
Table 121. Novartis International AG Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Novartis International AG Immuno-oncology Drugs Product Portfolios and Specifications
Table 123. Novartis International AG Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 124. Novartis International AG Main Business
Table 125. Novartis International AG Latest Developments
Table 126. AbbVie, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. AbbVie, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 128. AbbVie, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 129. AbbVie, Inc. Main Business
Table 130. AbbVie, Inc. Latest Developments
Table 131. Pfizer Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 132. Pfizer Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 133. Pfizer Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 134. Pfizer Inc. Main Business
Table 135. Pfizer Inc. Latest Developments
Table 136. Sanofi S.A. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 137. Sanofi S.A. Immuno-oncology Drugs Product Portfolios and Specifications
Table 138. Sanofi S.A. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 139. Sanofi S.A. Main Business
Table 140. Sanofi S.A. Latest Developments
Table 141. EMD Serono, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 142. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 143. EMD Serono, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 144. EMD Serono, Inc. Main Business
Table 145. EMD Serono, Inc. Latest Developments
Table 146. Gilead Sciences Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 147. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 148. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 149. Gilead Sciences Inc. Main Business
Table 150. Gilead Sciences Inc. Latest Developments
Table 151. Prometheus Therapeutics & Diagnostics Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 152. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolios and Specifications
Table 153. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 154. Prometheus Therapeutics & Diagnostics Main Business
Table 155. Prometheus Therapeutics & Diagnostics Latest Developments
Table 156. Aduro BioTech Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 157. Aduro BioTech Immuno-oncology Drugs Product Portfolios and Specifications
Table 158. Aduro BioTech Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 159. Aduro BioTech Main Business
Table 160. Aduro BioTech Latest Developments
Table 161. Galena Biopharma Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 162. Galena Biopharma Immuno-oncology Drugs Product Portfolios and Specifications
Table 163. Galena Biopharma Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 164. Galena Biopharma Main Business
Table 165. Galena Biopharma Latest Developments
Table 166. Bavarian Nordic Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 167. Bavarian Nordic Immuno-oncology Drugs Product Portfolios and Specifications
Table 168. Bavarian Nordic Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 169. Bavarian Nordic Main Business
Table 170. Bavarian Nordic Latest Developments
Table 171. Celldex Therapeutics Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 172. Celldex Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
Table 173. Celldex Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 174. Celldex Therapeutics Main Business
Table 175. Celldex Therapeutics Latest Developments
Table 176. ImmunoCellular Therapeutics Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 177. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
Table 178. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 179. ImmunoCellular Therapeutics Main Business
Table 180. ImmunoCellular Therapeutics Latest Developments
Table 181. Incyte Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 182. Incyte Immuno-oncology Drugs Product Portfolios and Specifications
Table 183. Incyte Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 184. Incyte Main Business
Table 185. Incyte Latest Developments
Table 186. Dendreon Corporation Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 187. Dendreon Corporation Immuno-oncology Drugs Product Portfolios and Specifications
Table 188. Dendreon Corporation Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 189. Dendreon Corporation Main Business
Table 190. Dendreon Corporation Latest Developments
Table 191. Agilent Technologies Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 192. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 193. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 194. Agilent Technologies Inc. Main Business
Table 195. Agilent Technologies Inc. Latest Developments
Table 196. Agenus Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 197. Agenus Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 198. Agenus Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 199. Agenus Inc. Main Business
Table 200. Agenus Inc. Latest Developments
Table 201. Enzo Biochem, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 202. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 203. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 204. Enzo Biochem, Inc. Main Business
Table 205. Enzo Biochem, Inc. Latest Developments
Table 206. Lonza Group Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 207. Lonza Group Immuno-oncology Drugs Product Portfolios and Specifications
Table 208. Lonza Group Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 209. Lonza Group Main Business
Table 210. Lonza Group Latest Developments
Table 211. Bio-Rad Laboratories, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 212. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 213. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 214. Bio-Rad Laboratories, Inc. Main Business
Table 215. Bio-Rad Laboratories, Inc. Latest Developments
Table 216. Avantor, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 217. Avantor, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 218. Avantor, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 219. Avantor, Inc. Main Business
Table 220. Avantor, Inc. Latest Developments
Table 221. Spring Bank Pharmaceuticals, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 222. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 223. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 224. Spring Bank Pharmaceuticals, Inc. Main Business
Table 225. Spring Bank Pharmaceuticals, Inc. Latest Developments
Table 226. Ferring Pharmaceuticals Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 227. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolios and Specifications
Table 228. Ferring Pharmaceuticals Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 229. Ferring Pharmaceuticals Main Business
Table 230. Ferring Pharmaceuticals Latest Developments
Table 1. Immuno-oncology Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Immuno-oncology Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Immune Checkpoint Inhibitors
Table 4. Major Players of Immune System Modulators
Table 5. Major Players of Cancer Vaccines
Table 6. Major Players of Oncolytic Virus
Table 7. Major Players of Others
Table 8. Global Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 9. Global Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Table 10. Global Immuno-oncology Drugs Revenue by Type (2018-2023) & ($ million)
Table 11. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2023)
Table 12. Global Immuno-oncology Drugs Sale Price by Type (2018-2023) & (USD/Unit)
Table 13. Global Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 14. Global Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Table 15. Global Immuno-oncology Drugs Revenue by Application (2018-2023)
Table 16. Global Immuno-oncology Drugs Revenue Market Share by Application (2018-2023)
Table 17. Global Immuno-oncology Drugs Sale Price by Application (2018-2023) & (USD/Unit)
Table 18. Global Immuno-oncology Drugs Sales by Company (2018-2023) & (K Units)
Table 19. Global Immuno-oncology Drugs Sales Market Share by Company (2018-2023)
Table 20. Global Immuno-oncology Drugs Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Immuno-oncology Drugs Revenue Market Share by Company (2018-2023)
Table 22. Global Immuno-oncology Drugs Sale Price by Company (2018-2023) & (USD/Unit)
Table 23. Key Manufacturers Immuno-oncology Drugs Producing Area Distribution and Sales Area
Table 24. Players Immuno-oncology Drugs Products Offered
Table 25. Immuno-oncology Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Immuno-oncology Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Immuno-oncology Drugs Sales Market Share Geographic Region (2018-2023)
Table 30. Global Immuno-oncology Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Immuno-oncology Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Immuno-oncology Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Immuno-oncology Drugs Sales Market Share by Country/Region (2018-2023)
Table 34. Global Immuno-oncology Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Immuno-oncology Drugs Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Immuno-oncology Drugs Sales by Country (2018-2023) & (K Units)
Table 37. Americas Immuno-oncology Drugs Sales Market Share by Country (2018-2023)
Table 38. Americas Immuno-oncology Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Immuno-oncology Drugs Revenue Market Share by Country (2018-2023)
Table 40. Americas Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 41. Americas Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 42. APAC Immuno-oncology Drugs Sales by Region (2018-2023) & (K Units)
Table 43. APAC Immuno-oncology Drugs Sales Market Share by Region (2018-2023)
Table 44. APAC Immuno-oncology Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Immuno-oncology Drugs Revenue Market Share by Region (2018-2023)
Table 46. APAC Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 47. APAC Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 48. Europe Immuno-oncology Drugs Sales by Country (2018-2023) & (K Units)
Table 49. Europe Immuno-oncology Drugs Sales Market Share by Country (2018-2023)
Table 50. Europe Immuno-oncology Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Immuno-oncology Drugs Revenue Market Share by Country (2018-2023)
Table 52. Europe Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 53. Europe Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Immuno-oncology Drugs Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Immuno-oncology Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Immuno-oncology Drugs Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Immuno-oncology Drugs Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Immuno-oncology Drugs Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Immuno-oncology Drugs
Table 61. Key Market Challenges & Risks of Immuno-oncology Drugs
Table 62. Key Industry Trends of Immuno-oncology Drugs
Table 63. Immuno-oncology Drugs Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Immuno-oncology Drugs Distributors List
Table 66. Immuno-oncology Drugs Customer List
Table 67. Global Immuno-oncology Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Immuno-oncology Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Immuno-oncology Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Immuno-oncology Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Immuno-oncology Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Immuno-oncology Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Immuno-oncology Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Immuno-oncology Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Immuno-oncology Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Immuno-oncology Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Immuno-oncology Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Immuno-oncology Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Immuno-oncology Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Immuno-oncology Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Amgen, Inc Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Amgen, Inc Immuno-oncology Drugs Product Portfolios and Specifications
Table 83. Amgen, Inc Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. Amgen, Inc Main Business
Table 85. Amgen, Inc Latest Developments
Table 86. AstraZeneca, Plc Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolios and Specifications
Table 88. AstraZeneca, Plc Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. AstraZeneca, Plc Main Business
Table 90. AstraZeneca, Plc Latest Developments
Table 91. Bristol-Myers Squibb Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolios and Specifications
Table 93. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. Bristol-Myers Squibb Main Business
Table 95. Bristol-Myers Squibb Latest Developments
Table 96. Celgene Corporation Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Celgene Corporation Immuno-oncology Drugs Product Portfolios and Specifications
Table 98. Celgene Corporation Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. Celgene Corporation Main Business
Table 100. Celgene Corporation Latest Developments
Table 101. Eli Lilly and Company Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Eli Lilly and Company Immuno-oncology Drugs Product Portfolios and Specifications
Table 103. Eli Lilly and Company Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. Eli Lilly and Company Main Business
Table 105. Eli Lilly and Company Latest Developments
Table 106. Merck & Co. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Merck & Co. Immuno-oncology Drugs Product Portfolios and Specifications
Table 108. Merck & Co. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. Merck & Co. Main Business
Table 110. Merck & Co. Latest Developments
Table 111. Hoffmann-La Roche AG Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolios and Specifications
Table 113. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 114. Hoffmann-La Roche AG Main Business
Table 115. Hoffmann-La Roche AG Latest Developments
Table 116. Johnson & Johnson Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Johnson & Johnson Immuno-oncology Drugs Product Portfolios and Specifications
Table 118. Johnson & Johnson Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 119. Johnson & Johnson Main Business
Table 120. Johnson & Johnson Latest Developments
Table 121. Novartis International AG Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Novartis International AG Immuno-oncology Drugs Product Portfolios and Specifications
Table 123. Novartis International AG Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 124. Novartis International AG Main Business
Table 125. Novartis International AG Latest Developments
Table 126. AbbVie, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. AbbVie, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 128. AbbVie, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 129. AbbVie, Inc. Main Business
Table 130. AbbVie, Inc. Latest Developments
Table 131. Pfizer Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 132. Pfizer Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 133. Pfizer Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 134. Pfizer Inc. Main Business
Table 135. Pfizer Inc. Latest Developments
Table 136. Sanofi S.A. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 137. Sanofi S.A. Immuno-oncology Drugs Product Portfolios and Specifications
Table 138. Sanofi S.A. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 139. Sanofi S.A. Main Business
Table 140. Sanofi S.A. Latest Developments
Table 141. EMD Serono, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 142. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 143. EMD Serono, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 144. EMD Serono, Inc. Main Business
Table 145. EMD Serono, Inc. Latest Developments
Table 146. Gilead Sciences Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 147. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 148. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 149. Gilead Sciences Inc. Main Business
Table 150. Gilead Sciences Inc. Latest Developments
Table 151. Prometheus Therapeutics & Diagnostics Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 152. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolios and Specifications
Table 153. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 154. Prometheus Therapeutics & Diagnostics Main Business
Table 155. Prometheus Therapeutics & Diagnostics Latest Developments
Table 156. Aduro BioTech Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 157. Aduro BioTech Immuno-oncology Drugs Product Portfolios and Specifications
Table 158. Aduro BioTech Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 159. Aduro BioTech Main Business
Table 160. Aduro BioTech Latest Developments
Table 161. Galena Biopharma Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 162. Galena Biopharma Immuno-oncology Drugs Product Portfolios and Specifications
Table 163. Galena Biopharma Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 164. Galena Biopharma Main Business
Table 165. Galena Biopharma Latest Developments
Table 166. Bavarian Nordic Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 167. Bavarian Nordic Immuno-oncology Drugs Product Portfolios and Specifications
Table 168. Bavarian Nordic Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 169. Bavarian Nordic Main Business
Table 170. Bavarian Nordic Latest Developments
Table 171. Celldex Therapeutics Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 172. Celldex Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
Table 173. Celldex Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 174. Celldex Therapeutics Main Business
Table 175. Celldex Therapeutics Latest Developments
Table 176. ImmunoCellular Therapeutics Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 177. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolios and Specifications
Table 178. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 179. ImmunoCellular Therapeutics Main Business
Table 180. ImmunoCellular Therapeutics Latest Developments
Table 181. Incyte Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 182. Incyte Immuno-oncology Drugs Product Portfolios and Specifications
Table 183. Incyte Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 184. Incyte Main Business
Table 185. Incyte Latest Developments
Table 186. Dendreon Corporation Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 187. Dendreon Corporation Immuno-oncology Drugs Product Portfolios and Specifications
Table 188. Dendreon Corporation Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 189. Dendreon Corporation Main Business
Table 190. Dendreon Corporation Latest Developments
Table 191. Agilent Technologies Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 192. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 193. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 194. Agilent Technologies Inc. Main Business
Table 195. Agilent Technologies Inc. Latest Developments
Table 196. Agenus Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 197. Agenus Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 198. Agenus Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 199. Agenus Inc. Main Business
Table 200. Agenus Inc. Latest Developments
Table 201. Enzo Biochem, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 202. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 203. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 204. Enzo Biochem, Inc. Main Business
Table 205. Enzo Biochem, Inc. Latest Developments
Table 206. Lonza Group Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 207. Lonza Group Immuno-oncology Drugs Product Portfolios and Specifications
Table 208. Lonza Group Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 209. Lonza Group Main Business
Table 210. Lonza Group Latest Developments
Table 211. Bio-Rad Laboratories, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 212. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 213. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 214. Bio-Rad Laboratories, Inc. Main Business
Table 215. Bio-Rad Laboratories, Inc. Latest Developments
Table 216. Avantor, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 217. Avantor, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 218. Avantor, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 219. Avantor, Inc. Main Business
Table 220. Avantor, Inc. Latest Developments
Table 221. Spring Bank Pharmaceuticals, Inc. Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 222. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolios and Specifications
Table 223. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 224. Spring Bank Pharmaceuticals, Inc. Main Business
Table 225. Spring Bank Pharmaceuticals, Inc. Latest Developments
Table 226. Ferring Pharmaceuticals Basic Information, Immuno-oncology Drugs Manufacturing Base, Sales Area and Its Competitors
Table 227. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolios and Specifications
Table 228. Ferring Pharmaceuticals Immuno-oncology Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 229. Ferring Pharmaceuticals Main Business
Table 230. Ferring Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Immuno-oncology Drugs
Figure 2. Immuno-oncology Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immuno-oncology Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Immuno-oncology Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Immuno-oncology Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Immune Checkpoint Inhibitors
Figure 10. Product Picture of Immune System Modulators
Figure 11. Product Picture of Cancer Vaccines
Figure 12. Product Picture of Oncolytic Virus
Figure 13. Product Picture of Others
Figure 14. Global Immuno-oncology Drugs Sales Market Share by Type in 2022
Figure 15. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2023)
Figure 16. Immuno-oncology Drugs Consumed in Hospitals
Figure 17. Global Immuno-oncology Drugs Market: Hospitals (2018-2023) & (K Units)
Figure 18. Immuno-oncology Drugs Consumed in Clinics
Figure 19. Global Immuno-oncology Drugs Market: Clinics (2018-2023) & (K Units)
Figure 20. Immuno-oncology Drugs Consumed in Ambulatory Surgical Centers
Figure 21. Global Immuno-oncology Drugs Market: Ambulatory Surgical Centers (2018-2023) & (K Units)
Figure 22. Global Immuno-oncology Drugs Sales Market Share by Application (2022)
Figure 23. Global Immuno-oncology Drugs Revenue Market Share by Application in 2022
Figure 24. Immuno-oncology Drugs Sales Market by Company in 2022 (K Units)
Figure 25. Global Immuno-oncology Drugs Sales Market Share by Company in 2022
Figure 26. Immuno-oncology Drugs Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Immuno-oncology Drugs Revenue Market Share by Company in 2022
Figure 28. Global Immuno-oncology Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Immuno-oncology Drugs Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 31. Americas Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 32. APAC Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 33. APAC Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 34. Europe Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 35. Europe Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 38. Americas Immuno-oncology Drugs Sales Market Share by Country in 2022
Figure 39. Americas Immuno-oncology Drugs Revenue Market Share by Country in 2022
Figure 40. Americas Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 41. Americas Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 42. United States Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Immuno-oncology Drugs Sales Market Share by Region in 2022
Figure 47. APAC Immuno-oncology Drugs Revenue Market Share by Regions in 2022
Figure 48. APAC Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 49. APAC Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 50. China Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Immuno-oncology Drugs Sales Market Share by Country in 2022
Figure 58. Europe Immuno-oncology Drugs Revenue Market Share by Country in 2022
Figure 59. Europe Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 60. Europe Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 61. Germany Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Immuno-oncology Drugs Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 70. Egypt Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Immuno-oncology Drugs in 2022
Figure 76. Manufacturing Process Analysis of Immuno-oncology Drugs
Figure 77. Industry Chain Structure of Immuno-oncology Drugs
Figure 78. Channels of Distribution
Figure 79. Global Immuno-oncology Drugs Sales Market Forecast by Region (2024-2029)
Figure 80. Global Immuno-oncology Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Immuno-oncology Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Immuno-oncology Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Immuno-oncology Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Immuno-oncology Drugs Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Immuno-oncology Drugs
Figure 2. Immuno-oncology Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immuno-oncology Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Immuno-oncology Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Immuno-oncology Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Immune Checkpoint Inhibitors
Figure 10. Product Picture of Immune System Modulators
Figure 11. Product Picture of Cancer Vaccines
Figure 12. Product Picture of Oncolytic Virus
Figure 13. Product Picture of Others
Figure 14. Global Immuno-oncology Drugs Sales Market Share by Type in 2022
Figure 15. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2023)
Figure 16. Immuno-oncology Drugs Consumed in Hospitals
Figure 17. Global Immuno-oncology Drugs Market: Hospitals (2018-2023) & (K Units)
Figure 18. Immuno-oncology Drugs Consumed in Clinics
Figure 19. Global Immuno-oncology Drugs Market: Clinics (2018-2023) & (K Units)
Figure 20. Immuno-oncology Drugs Consumed in Ambulatory Surgical Centers
Figure 21. Global Immuno-oncology Drugs Market: Ambulatory Surgical Centers (2018-2023) & (K Units)
Figure 22. Global Immuno-oncology Drugs Sales Market Share by Application (2022)
Figure 23. Global Immuno-oncology Drugs Revenue Market Share by Application in 2022
Figure 24. Immuno-oncology Drugs Sales Market by Company in 2022 (K Units)
Figure 25. Global Immuno-oncology Drugs Sales Market Share by Company in 2022
Figure 26. Immuno-oncology Drugs Revenue Market by Company in 2022 ($ Million)
Figure 27. Global Immuno-oncology Drugs Revenue Market Share by Company in 2022
Figure 28. Global Immuno-oncology Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 29. Global Immuno-oncology Drugs Revenue Market Share by Geographic Region in 2022
Figure 30. Americas Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 31. Americas Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 32. APAC Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 33. APAC Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 34. Europe Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 35. Europe Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 36. Middle East & Africa Immuno-oncology Drugs Sales 2018-2023 (K Units)
Figure 37. Middle East & Africa Immuno-oncology Drugs Revenue 2018-2023 ($ Millions)
Figure 38. Americas Immuno-oncology Drugs Sales Market Share by Country in 2022
Figure 39. Americas Immuno-oncology Drugs Revenue Market Share by Country in 2022
Figure 40. Americas Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 41. Americas Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 42. United States Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Canada Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Mexico Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Brazil Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. APAC Immuno-oncology Drugs Sales Market Share by Region in 2022
Figure 47. APAC Immuno-oncology Drugs Revenue Market Share by Regions in 2022
Figure 48. APAC Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 49. APAC Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 50. China Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. Japan Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. South Korea Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. Southeast Asia Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. India Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Australia Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. China Taiwan Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. Europe Immuno-oncology Drugs Sales Market Share by Country in 2022
Figure 58. Europe Immuno-oncology Drugs Revenue Market Share by Country in 2022
Figure 59. Europe Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 60. Europe Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 61. Germany Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. France Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. UK Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Italy Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Russia Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Country in 2022
Figure 67. Middle East & Africa Immuno-oncology Drugs Revenue Market Share by Country in 2022
Figure 68. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Type (2018-2023)
Figure 69. Middle East & Africa Immuno-oncology Drugs Sales Market Share by Application (2018-2023)
Figure 70. Egypt Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. South Africa Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Israel Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Turkey Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. GCC Country Immuno-oncology Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Immuno-oncology Drugs in 2022
Figure 76. Manufacturing Process Analysis of Immuno-oncology Drugs
Figure 77. Industry Chain Structure of Immuno-oncology Drugs
Figure 78. Channels of Distribution
Figure 79. Global Immuno-oncology Drugs Sales Market Forecast by Region (2024-2029)
Figure 80. Global Immuno-oncology Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 81. Global Immuno-oncology Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 82. Global Immuno-oncology Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 83. Global Immuno-oncology Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 84. Global Immuno-oncology Drugs Revenue Market Share Forecast by Application (2024-2029)
